Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Public ClinicalTrials.gov record NCT03502668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules.
Study identification
- NCT ID
- NCT03502668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2018 (Actual)
- Primary completion
- Jan 13, 2026 (Actual)
- Completion
- Jan 13, 2026 (Actual)
- Last update posted
- Apr 3, 2026
2018 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Colorado, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| BRCR Medical Center Inc. | Plantation | Florida | 33324 | — |
| Moffitt Cancer Center Site#507 | Tampa | Florida | 33612 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University Health Hospital - Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Clinical Research Center | Westwood | Kansas | 66205 | — |
| The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division) | Bethesda | Maryland | 20817 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Oregon Health and Science University Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center - Hematology-Oncology | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03502668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03502668 live on ClinicalTrials.gov.